Cipla receives FDA OK for generic Somatuline Depot
Cipla’s lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.
Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.
Lanreotide Injection is supplied as 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml single-dose, pre-filled, ready-to- inject syringe.
Cipla’s lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.
[Read more: Cipla wins FDA OK for generic Imitrex]
Somatuline depot (lanreotide) had a market value of approximately $898 million for the 12-month period ending March 2024, per IQVIA.
[Read more: Cipla gets FDA nod for generic Migranal]